No records
|
650 |
Jufri M., Vardhani A., Purwaningsih E. |
55542805100;57372533300;57186723500; |
Evaluating the efficacy of lotion containing black rice bran (Oryza sativa L. indica) extract as skin brightening agent: A clinical trial |
2021 |
Jundishapur Journal of Natural Pharmaceutical Products |
16 |
4 |
e114152 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121121214&doi=10.5812%2fjjnpp.114152&partnerID=40&md5=7475812ecd399617effa3198e4bc8700 |
Faculty of Pharmacy, Universitas Indonesia, Indonesia; Department of Pharmacy, Faculty of Medicine, Universitas Indonesia, Indonesia |
Jufri, M., Faculty of Pharmacy, Universitas Indonesia, Indonesia; Vardhani, A., Faculty of Pharmacy, Universitas Indonesia, Indonesia; Purwaningsih, E., Department of Pharmacy, Faculty of Medicine, Universitas Indonesia, Indonesia |
Background: Ultraviolet exposure is an extrinsic factor to initiate melanogenesis, the process of melanin formation in the skin. Nowadays, natural ingredients tend to be more prevalent in cosmetic formulations due to consumers’ concern about synthetic ingredients and the risks they may represent for human health. Rice bran, the outer layer of a rice grain, can be utilized as a skin-lightening agent. Objectives: This study aimed to determine the efficacy of a lotion containing black rice bran (Oryza sativa L. indica) ethanolic extract as a skin lightening agent. Methods: The black rice bran ethanolic extract was formulated into oil in water (o/w) lotion. In this study, 34 women applied the lotion at one side of the forearm and base placebo lotion as control at the other side of forearm. The results were tested with a paired t-test by GraphPad Prism 8.3.0 software. Results: There was a significant decrease in the melanin index and erythema index in the forearm with a lotion containing black rice bran extract (P-value < 0.0001). Conclusions: The lotion containing 10% black rice bran extract was effective as a skin lightener because it effectively reduced skin melanin production when applied topically. Copyright © 2021, Author(s). |
Black Rice Bran; Clinical Trials; Natural Product; Oryza sativa L. indica; Skin Lightening Agent |
|
Kowsar Medical Institute |
17357780 |
|
|
Article |
Q3 |
228 |
17746 |
|
|
662 |
Ta J.W.C., Chew D.P., Tsui K.L., Tan D., Duplyakov D., Hammoudeh A., Zhang B., Li Y., Xu K., Ong P.J., Firman D., Gamra H., Almahmeed W., Dalal J., Tam L.-W., Steg G., Nguyen Q.N., Ako J., Al Suwaidi J., Chan M., Sobhy M., Shehab A., Buddhari W., Wang Z., Fong A.Y.Y., Karadag B., Kim B.-K., Baber U., Chin C.T., Han Y.L. |
57354736300;7102026332;7101671562;50263435900;6506125408;8088443300;56637270100;55914058500;56510776700;7102312670;54898724100;7004594521;6506558682;7004278395;56585509700;57197860836;39962151600;6701389098;6603728555;23388249600;55345664600;6603838351;57192991797;8875501800;14321654600;56243107600;35189204900;16047315200;57226594604;57211831338; |
2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations |
2021 |
European Cardiology Review |
16 |
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119968735&doi=10.15420%2fecr.2021.35&partnerID=40&md5=0f474aea7166811035b920e727476fae |
National Heart Centre, Singapore; Sengkang General Hospital, Singapore; College of Medicine and Public Health, Flinders University, Adelaide, Australia; Pamela Youde Nethersole Eastern Hospital, Hong Kong; Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore; Samara Regional Cardiology Dispensary, Samara, Russian Federation; Cardiology Department, Istishari Hospital, Amman, Jordan; Department of Cardiology, First Affiliated Hospital, Dalian Medical University, Dalian, China; Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China; Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Heart Specialist International, Mount Elizabeth Novena Hospital, Singapore; Tan Tock Seng Hospital, Singapore; Harapan Kita National Cardiovascular Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia Harapan Kita, Jakarta, Indonesia; Cardiology Department, Fattouma Bourguiba University Hospital, University of Monastir, Monastir, Tunisia; Cleveland Clinic Abu Dhabi, United Arab Emirates; Centre for Cardiac Sciences, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India; Kwong Wah Hospital, Hong Kong; Department of Cardiology, Hôpital Bichat, Paris, France; Department of Cardiology, Hanoi Medical University, Hanoi, Viet Nam; Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan; Adult Cardiology, Hamad Medical Corporation, Doha, Qatar; National University Heart Centre, Singapore; Faculty of Medicine, Alexandria University, Egypt; College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates; King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Sarawak Heart Centre, Kota Samarahan, Malaysia; Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea; University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States |
Ta, J.W.C., National Heart Centre, Singapore, Sengkang General Hospital, Singapore; Chew, D.P., College of Medicine and Public Health, Flinders University, Adelaide, Australia; Tsui, K.L., Pamela Youde Nethersole Eastern Hospital, Hong Kong; Tan, D., Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore; Duplyakov, D., Samara Regional Cardiology Dispensary, Samara, Russian Federation; Hammoudeh, A., Cardiology Department, Istishari Hospital, Amman, Jordan; Zhang, B., Department of Cardiology, First Affiliated Hospital, Dalian Medical University, Dalian, China; Li, Y., Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China; Xu, K., Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Ong, P.J., Heart Specialist International, Mount Elizabeth Novena Hospital, Singapore, Tan Tock Seng Hospital, Singapore; Firman, D., Harapan Kita National Cardiovascular Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia Harapan Kita, Jakarta, Indonesia; Gamra, H., Cardiology Department, Fattouma Bourguiba University Hospital, University of Monastir, Monastir, Tunisia; Almahmeed, W., Cleveland Clinic Abu Dhabi, United Arab Emirates; Dalal, J., Centre for Cardiac Sciences, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India; Tam, L.-W., Kwong Wah Hospital, Hong Kong; Steg, G., Department of Cardiology, Hôpital Bichat, Paris, France; Nguyen, Q.N., Department of Cardiology, Hanoi Medical University, Hanoi, Viet Nam; Ako, J., Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan; Al Suwaidi, J., Adult Cardiology, Hamad Medical Corporation, Doha, Qatar; Chan, M., National University Heart Centre, Singapore; Sobhy, M., Faculty of Medicine, Alexandria University, Egypt; Shehab, A., College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates; Buddhari, W., King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Wang, Z., Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Fong, A.Y.Y., Sarawak Heart Centre, Kota Samarahan, Malaysia; Karadag, B., Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; Kim, B.-K., Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea; Baber, U., University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Chin, C.T., National Heart Centre, Singapore; Han, Y.L., Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China |
Advanced age, diabetes, and chronic kidney disease not only increase the risk for ischaemic events in chronic coronary syndromes (CCS) but also confer a high bleeding risk during antiplatelet therapy. These special populations may warrant modification of therapy, especially among Asians, who have displayed characteristics that are clinically distinct from Western patients. Previous guidance has been provided regarding the classification of high-risk CCS and the use of newer-generation P2Y12inhibitors (i.e. ticagrelor and prasugrel) after acute coronary syndromes (ACS) in Asia. The authors summarise evidence on the use of these P2Y12inhibitors during the transition from ACS to CCS and among special populations. Specifically, they present recommendations on the roles of standard dual antiplatelet therapy, shortened dual antiplatelet therapy and single antiplatelet therapy among patients with coronary artery disease, who are either transitioning from ACS to CCS; elderly; or with chronic kidney disease, diabetes, multivessel coronary artery disease and bleeding events during therapy. © 2021 Radcliffe Group Ltd. All rights reserved. |
Asia; Comorbidity; Consensus; Dual antiplatelet therapy; Myocardial ischaemia; Platelet aggregation inhibitors |
|
Radcliffe Medical Media |
17583756 |
|
|
Article |
Q2 |
864 |
5422 |
|
|
698 |
Susanto A.D., Rozaliyani A., Prasetyo B., Agustin H., Baskoro H., Arifin A.R., Pratama S., Zaini J., Hasto B.D., Ratmono T., Savitri A.I., Samoedro E., Husain B., Nawas A., Burhan E. |
57190425587;57203065912;57193735900;56135125000;56436836700;57223139966;57288146100;57221833355;57210897107;57288146200;56401804100;57192995312;57287062900;36490293900;36058554600; |
Epidemiological and clinical features of covid-19 patients at national emergency hospital wisma atlet kemayoran, jakarta, Indonesia |
2021 |
Kesmas |
16 |
|
|
11 |
16 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116538242&doi=10.21109%2fkesmas.v0i0.5233&partnerID=40&md5=82245a20a3432d82a3f500c9b5968696 |
National Medical Team COVID-19, the Indonesian Society of Respirology, Jakarta, Indonesia; Department of Pulmonology and Respiratory Medicine, Persahabatan General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; National Emergency Hospital Wisma Atlet Kemayoran, Jakarta, Indonesia; Siena Clinical: Academic Research Organization, Jakarta, Indonesia |
Susanto, A.D., National Medical Team COVID-19, the Indonesian Society of Respirology, Jakarta, Indonesia, Department of Pulmonology and Respiratory Medicine, Persahabatan General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Rozaliyani, A., National Medical Team COVID-19, the Indonesian Society of Respirology, Jakarta, Indonesia; Prasetyo, B., Department of Pulmonology and Respiratory Medicine, Persahabatan General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Agustin, H., Department of Pulmonology and Respiratory Medicine, Persahabatan General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Baskoro, H., National Medical Team COVID-19, the Indonesian Society of Respirology, Jakarta, Indonesia, Department of Pulmonology and Respiratory Medicine, Persahabatan General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Arifin, A.R., National Medical Team COVID-19, the Indonesian Society of Respirology, Jakarta, Indonesia, National Emergency Hospital Wisma Atlet Kemayoran, Jakarta, Indonesia; Pratama, S., National Medical Team COVID-19, the Indonesian Society of Respirology, Jakarta, Indonesia, National Emergency Hospital Wisma Atlet Kemayoran, Jakarta, Indonesia; Zaini, J., National Medical Team COVID-19, the Indonesian Society of Respirology, Jakarta, Indonesia, Department of Pulmonology and Respiratory Medicine, Persahabatan General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Hasto, B.D., National Emergency Hospital Wisma Atlet Kemayoran, Jakarta, Indonesia; Ratmono, T., National Emergency Hospital Wisma Atlet Kemayoran, Jakarta, Indonesia; Savitri, A.I., Siena Clinical: Academic Research Organization, Jakarta, Indonesia; Samoedro, E., National Medical Team COVID-19, the Indonesian Society of Respirology, Jakarta, Indonesia; Husain, B., National Medical Team COVID-19, the Indonesian Society of Respirology, Jakarta, Indonesia; Nawas, A., Department of Pulmonology and Respiratory Medicine, Persahabatan General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Burhan, E., National Medical Team COVID-19, the Indonesian Society of Respirology, Jakarta, Indonesia, Department of Pulmonology and Respiratory Medicine, Persahabatan General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia |
The emergency hospital is intended to prevent transmission of COVID-19 in the community by isolating patients without symptoms, with mild or moderate symptoms. This study evaluated the clinical characteristics and outcomes of COVID-19 patients who were admitted to this facility. This retrospective study re-viewed data of patients treated at the National Emergency Hospital Wisma Atlet Kemayoran in Jakarta, Indonesia, from March 23 to April 30, 2020. Patient characteristics (clinical symptoms, laboratory test results, Chest X-Ray, SARS-CoV-2 immunoserology, and RT-PCR results from nasopharyngeal/ oropharyngeal preparations) were compared between severity groups. There were 413 COVID-19 cases analyzed, of which 190 (46%) were asymptomatic, 93 (22.5%) were mild, and 130 (31.5%) were moderate cases. Most asymptomatic cases were male, with young age, and without comorbidity. Mild cases were dominated by female and young patients, while most moderate cases were male and older patients. The number of patients with comorbidities was higher in mild and mod-erate cases. The patient's overall outcome was good and did not differ based on the severity of symptoms. Despite the many challenges, patients with moderate symptoms can be safely treated in the emergency hospital. © 2021 Sciendo. All rights reserved. |
Asymptomatic; COVID-19; Emergency hospital |
|
Universitas Indonesia, Faculty of public health |
19077505 |
|
|
Article |
Q4 |
146 |
23606 |
|
|
765 |
Tan J.W.C., Chew D.P., Brieger D., Eikelboom J., Montalescot G., Ako J., Kim B.-K., Quek D.K.L., Aitken S.J., Chow C.K., Chour S., Tse H.F., Kaul U., Firdaus I., Kubo T., Liew B.W., Chong T.T., Sin K.Y.K., Yeh H.-I., Buddhari W., Chunhamaneewat N., Hasan F., Fox K.A.A., Nguyen Q.N., Lo S.T.H. |
14829599000;7102026332;7004107910;7006303000;7102302494;6701389098;35189204900;57213290935;57225921713;8871779800;57225956090;7006070805;7102340294;55796864700;57226325834;57205155828;36609879000;57223949258;57225966367;57192991797;6505509528;57225971750;57224650893;39962151600;7401542169; |
2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome |
2021 |
European Cardiology Review |
16 |
|
e26 |
|
|
|
3 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109820982&doi=10.15420%2fECR.2020.45&partnerID=40&md5=349f92694e4c018a59343a627d38ced6 |
National Heart Centre, Singapore, Singapore; Sengkang General Hospital, Singapore, Singapore; College of Medicine and Public Health, Flinders University, Adelaide, Australia; Concord Repatriation General Hospital, University of Sydney, Sydney, Australia; McMaster UniversityON, Canada; Sorbonne University, Paris, France; ACTION Study Group, France; Pitié-Salpêtrière University Hospital (AP-HP), Paris, France; Kitasato University and Hospital, Kanagawa, Japan; Yonsei University College of Medicine, South Korea; Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; University of Sydney, Sydney, Australia; Westmead Applied Research Centre, University of Sydney, Sydney, Australia; Westmead Hospital, Sydney, Australia; Calmette Hospital, Phnom Penh, Cambodia; Queen Mary Hospital, University of Hong Kong, Hong Kong; Batra Hospital and Medical Research Center, New Delhi, India; Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Wakayama Medical University, Wakayama, Japan; Changi General Hospital, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore; MacKay Memorial Hospital, MacKay Medical College, Taipei, Taiwan; King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Siriraj Hospital, Mahidol University, Bangkok, Thailand; Heart & Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates; University of Edinburgh, Edinburgh, United Kingdom; Hanoi Medical University, Vietnam National Heart Institute, Hanoi, Viet Nam; Liverpool Hospital, Sydney, Australia |
Tan, J.W.C., National Heart Centre, Singapore, Singapore, Sengkang General Hospital, Singapore, Singapore; Chew, D.P., College of Medicine and Public Health, Flinders University, Adelaide, Australia; Brieger, D., Concord Repatriation General Hospital, University of Sydney, Sydney, Australia; Eikelboom, J., McMaster UniversityON, Canada; Montalescot, G., Sorbonne University, Paris, France, ACTION Study Group, France, Pitié-Salpêtrière University Hospital (AP-HP), Paris, France; Ako, J., Kitasato University and Hospital, Kanagawa, Japan; Kim, B.-K., Yonsei University College of Medicine, South Korea; Quek, D.K.L., Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; Aitken, S.J., University of Sydney, Sydney, Australia; Chow, C.K., Westmead Applied Research Centre, University of Sydney, Sydney, Australia, Westmead Hospital, Sydney, Australia; Chour, S., Calmette Hospital, Phnom Penh, Cambodia; Tse, H.F., Queen Mary Hospital, University of Hong Kong, Hong Kong; Kaul, U., Batra Hospital and Medical Research Center, New Delhi, India; Firdaus, I., Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Kubo, T., Wakayama Medical University, Wakayama, Japan; Liew, B.W., Changi General Hospital, Singapore, Singapore; Chong, T.T., Singapore General Hospital, Singapore, Singapore; Sin, K.Y.K., National Heart Centre, Singapore, Singapore; Yeh, H.-I., MacKay Memorial Hospital, MacKay Medical College, Taipei, Taiwan; Buddhari, W., King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Chunhamaneewat, N., Siriraj Hospital, Mahidol University, Bangkok, Thailand; Hasan, F., Heart & Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates; Fox, K.A.A., University of Edinburgh, Edinburgh, United Kingdom; Nguyen, Q.N., Hanoi Medical University, Vietnam National Heart Institute, Hanoi, Viet Nam; Lo, S.T.H., Liverpool Hospital, Sydney, Australia |
The unique characteristics of patients with chronic coronary syndrome (CCS) in the Asia-Pacific region, heterogeneous approaches because of differences in accesses and resources and low number of patients from the Asia-Pacific region in pivotal studies, mean that international guidelines cannot be routinely applied to these populations. The Asian Pacific Society of Cardiology developed these consensus recommendations to summarise current evidence on the management of CCS and provide recommendations to assist clinicians treat patients from the region. The consensus recommendations were developed by an expert consensus panel who reviewed and appraised the available literature, with focus on data from patients in Asia-Pacific. Consensus statements were developed then put to an online vote. The resulting recommendations provide guidance on the assessment and management of bleeding and ischaemic risks in Asian CCS patients. Furthermore, the selection of long-term antithrombotic therapy is discussed, including the role of single antiplatelet therapy, dual antiplatelet therapy and dual pathway inhibition therapy. © 2021 Radcliffe Group Ltd. All rights reserved. |
Anticoagulant; Antiplatelet; Asia-Pacific; Bleeding; Chronic coronary syndrome; Consensus; Ischaemia |
acetylsalicylic acid; anticoagulant agent; clopidogrel; prasugrel; ticagrelor; age; anticoagulant therapy; Article; Asia; bleeding risk score; brain hemorrhage; cardiac patient; consensus; coronary artery disease; dual antiplatelet therapy; gastrointestinal hemorrhage; heart muscle ischemia; high risk patient; human; percutaneous coronary intervention; thrombosis |
Radcliffe Medical Media |
17583756 |
|
|
Article |
Q2 |
864 |
5422 |
|
|
811 |
Dinarti L.K., Anggrahini D.W., Lilyasari O., Siswanto B.B., Hartopo A.B. |
57192908812;35285645700;57192914838;14422648800;36056281100; |
Pulmonary arterial hypertension in Indonesia: Current status and local application of international guidelines |
2021 |
Global Heart |
16 |
1 |
23 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105601627&doi=10.5334%2fGH.944&partnerID=40&md5=a344de6f2ae7c858408e0bbec6a2f09e |
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Dr. Sardjito Hospital, Yogyakarta, Indonesia; Department Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia |
Dinarti, L.K., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Dr. Sardjito Hospital, Yogyakarta, Indonesia; Anggrahini, D.W., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Dr. Sardjito Hospital, Yogyakarta, Indonesia; Lilyasari, O., Department Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Siswanto, B.B., Department Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Hartopo, A.B., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Dr. Sardjito Hospital, Yogyakarta, Indonesia |
Recent advances in the diagnosis and management of pulmonary arterial hypertension (PAH) have led to a significant improvement in the outcomes for patients with PAH. However, prompt and accurate diagnosis of PAH remains an unmet challenge due to lack of awareness and lack of meticulous data to profile the etiology and pathophysiology of this rare progressive disease, especially in low- and middle-income country. In Indonesia, the true prevalence and incidence of different subtypes of PAH in general population is still unknown. The Congenital HeARt Disease in adult and Pulmonary Hypertension (COHARD-PH) registry was the first single-center prospective registry in Indonesia, which indicated that almost 80% of adult patients with congenital heart disease (CHD) had experienced PAH and even Eisenmenger syndrome due to delayed diagnosis. Screening for early detection of asymptomatic CHD in children is yet to be systematically established in Indonesia, leading to undiagnosed and uncorrected CHD in adulthood. There are no specific national guidelines focusing on diagnostic workup and treatment of PAH in Indonesia. Furthermore, the lack of adequate diagnostic facilities, limited treatment availability, and limited drug coverage under the National Health Insurance Scheme are key issues that remain unaddressed. This review focuses on the diagnosis, treatment, and management of PAH associated with CHD in Indonesia as per international guidelines. We have proposed recommendations to effectively control and prevent PAH associated with CHD in Indonesia. The paper should be of interest to readers in the area of medical management and policy makers especially in low- and middle-income countries. © 2021 The Author(s). |
Congenital heart disease (CHD); Etiology; Indonesia; International guideline; Lower middle-income region; Pulmonary arterial hypertension (PAH) |
antihypertensive agent; vasodilator agent; clinical research; congenital heart disease; early diagnosis; health care policy; human; Indonesia; maternal mortality; practice guideline; priority journal; prognostic assessment; pulmonary hypertension; Review; risk assessment; adult; congenital heart malformation; Eisenmenger complex; female; pregnancy; pulmonary hypertension; Adult; Eisenmenger Complex; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Indonesia; Pregnancy; Pulmonary Arterial Hypertension |
Web Portal Ubiquity Press |
22118160 |
|
34040936 |
Review |
Q1 |
1012 |
4314 |
|
|
883 |
Harimurti K., Saldi S.R.F., Dewiasty E., Alfarizi T., Dharmayuli M., Khoeri M.M., Paramaiswari W.T., Salsabila K., Tafroji W., Halim C., Jiang Q., Gamil A., Safari D. |
23473513200;55201904000;55257705500;57221853325;57221841113;55994827400;57221097580;57192272141;57118271600;57221850899;36028184700;57202388319;23493586700; |
Streptococcus pneumoniae carriage and antibiotic susceptibility among Indonesian pilgrims during the Hajj pilgrimage in 2015 |
2021 |
PLoS ONE |
16 |
1 January |
e0246122 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100423019&doi=10.1371%2fjournal.pone.0246122&partnerID=40&md5=49970f6f2918134dc220f4fd13977bed |
Clinical Epidemiology and Evidence-Based Medicine (CEEBM) Unit, Cipto Mangunkusumo Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Department of Internal Medicine, Faculty of Medicine Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Center of Hajj Health, Ministry of Health, Jakarta, Indonesia; Eijkman Institute for Molecular Biology, Jakarta, Indonesia; Pfizer Indonesia, Jakarta, Indonesia; Pfizer Inc., Collegeville, PA, United States; Pfizer Inc., Emerging Markets Medical and Scientific Affairs, Dubai, United Arab Emirates |
Harimurti, K., Clinical Epidemiology and Evidence-Based Medicine (CEEBM) Unit, Cipto Mangunkusumo Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Saldi, S.R.F., Clinical Epidemiology and Evidence-Based Medicine (CEEBM) Unit, Cipto Mangunkusumo Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Dewiasty, E., Clinical Epidemiology and Evidence-Based Medicine (CEEBM) Unit, Cipto Mangunkusumo Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Alfarizi, T., Center of Hajj Health, Ministry of Health, Jakarta, Indonesia; Dharmayuli, M., Center of Hajj Health, Ministry of Health, Jakarta, Indonesia; Khoeri, M.M., Eijkman Institute for Molecular Biology, Jakarta, Indonesia; Paramaiswari, W.T., Eijkman Institute for Molecular Biology, Jakarta, Indonesia; Salsabila, K., Eijkman Institute for Molecular Biology, Jakarta, Indonesia; Tafroji, W., Eijkman Institute for Molecular Biology, Jakarta, Indonesia; Halim, C., Pfizer Indonesia, Jakarta, Indonesia; Jiang, Q., Pfizer Inc., Collegeville, PA, United States; Gamil, A., Pfizer Inc., Emerging Markets Medical and Scientific Affairs, Dubai, United Arab Emirates; Safari, D., Eijkman Institute for Molecular Biology, Jakarta, Indonesia |
The Hajj is an annual pilgrimage to Mecca and one of the largest gathering of people in the world. Most Indonesian pilgrims are senior adults and elderly adults, who are more prone to acquire infections during the Hajj ritual. The aims of this study are to investigate the dynamics of Streptococcus pneumoniae colonization and to investigate antibiotic susceptibility of pneumococcal strains in Indonesian pilgrims. This was a prospective multi-site longitudinal study in Indonesian hajj pilgrims aged >18 years old in the year 2015. Nasopharyngeal swabs were collected from the same subject before departure and upon arrival at the airport. S. pneumoniae was identified using conventional and molecular approach, while antibiotic susceptibility was determined using a disk diffusion method. Among 813 Hajj pilgrims who were enrolled from five sites in this study, the prevalence of S. pneumoniae carriage rates before- and after-the Hajj were 8.6% (95% CI 6.7–10.5%) and 8.2% (95% CI 6.4–10.1%), (p value: 0.844) respectively. Serotype 16F, 6A/6B, 3, 18, and 23F were the five most prevalent serotypes before Hajj, whereas serotypes 3, 34, 13, 4, and 23F were the most prevalent serotypes after Hajj. Serotype 3 was identified as most acquired serotype during Hajj in Indonesian pilgrim. There was an increase in the percentage of isolates susceptible to co-trimoxazole after Hajj (42.9% versus 57.4%). The study provided an overview of the change of dynamics of S. pneumoniae serotype acquisition in Indonesian Hajj Pilgrims. Along with data of vaccination serotypes coverage and antimicrobial susceptibility, these findings may contribute to recommendation of vaccination and treatment policies in the future. © 2021 Harimurti et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
|
chloramphenicol; clindamycin; cotrimoxazole; erythromycin; penicillin derivative; tetracycline; antiinfective agent; adult; airport; antibiotic sensitivity; Article; bacterial colonization; bacterial strain; bacterium isolate; controlled study; disk diffusion; female; human; Indonesian; longitudinal study; male; nasopharyngeal swab; nonhuman; prospective study; serotype; Streptococcus pneumoniae; adolescent; antibiotic resistance; clinical trial; crowding (area); growth, development and aging; heterozygote; Indonesia; isolation and purification; microbial sensitivity test; microbiology; middle aged; multicenter study; nasopharynx; pneumococcal infection; Streptococcus pneumoniae; Adolescent; Adult; Anti-Bacterial Agents; Carrier State; Crowding; Drug Resistance, Bacterial; Female; Humans; |
Public Library of Science |
19326203 |
|
33497410 |
Article |
Q1 |
990 |
4434 |
|
|
885 |
Prayitno A., Supriyatno B., Munasir Z., Karuniawati A., Hadinegoro S.R.S., Prihartono J., Safari D., Sundoro J., Khoeri M.M. |
57193342301;37068046400;7801694370;54886816200;57226218772;6602605635;23493586700;49762130000;55994827400; |
Pneumococcal nasopharyngeal carriage in Indonesia infants and toddlers post-PCV13 vaccination in a 2+1 schedule: A prospective cohort study |
2021 |
PLoS ONE |
16 |
1 January |
e0245789 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100392996&doi=10.1371%2fjournal.pone.0245789&partnerID=40&md5=cb78eb658b86a8f3be7a35fe8b7fd3cc |
Department of Pediatrics, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Department of Microbiology, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Department of Community Medicine, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Molecular Bacteriology, Eijkman Institute for Molecular Biology, Jakarta, Indonesia; Indonesian Technical Advisory Group on Immunization, Jakarta, Indonesia |
Prayitno, A., Department of Pediatrics, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Supriyatno, B., Department of Pediatrics, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Munasir, Z., Department of Pediatrics, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Karuniawati, A., Department of Microbiology, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Hadinegoro, S.R.S., Department of Pediatrics, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Prihartono, J., Department of Community Medicine, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Safari, D., Molecular Bacteriology, Eijkman Institute for Molecular Biology, Jakarta, Indonesia; Sundoro, J., Indonesian Technical Advisory Group on Immunization, Jakarta, Indonesia; Khoeri, M.M., Molecular Bacteriology, Eijkman Institute for Molecular Biology, Jakarta, Indonesia |
Background The PCV13 immunization demonstration program began in October 2017 in Indonesia. The aim of this study is to assess the dynamic changes of pneumococcal serotype before and after PCV13 administration, with two primary and one booster doses. Methods The prospective cohort study was conducted as a follow up study measuring the impact of PCV13 demonstration program by the Indonesian Ministry of Health in Lombok Island, West Nusa Tenggara, Indonesia, from March 2018 to June 2019. The subjects were two-month-old healthy infants who were brought to the primary care facility for routine vaccination and followed until 18 months of age. We use convenience sampling method. There were 115 infants in the control group and 118 infants in the vaccine group, and the PCV immunization was given on a 2+1 schedule. Nasopharyngeal (NP) swabs were collected four times during the vaccination periods by trained medical staff. Specimens were analyzed by culture methods to detect S. pneumonia colonization and multiplex polymerase chain reaction (mPCR) to determine serotype. The most frequently detected serotypes will be named as dominant serotypes. Descriptive analysis of demographic characteristics, the prevalence of overall and serotype colonization, and the distribution of serotypes were performed. The prevalence of both cohort groups were compared using chi-square test. Statistical significance was set at p < 0.05. Results Two hundred and thirty three infants age two months old were recruited, with 48.9% of the subjects were male and 51.1% of the subjects were female. Sociodemographic data in both cohort groups were relatively equal. Nasopharyngeal pneumococcal colonization before PCV13 administration occurred in 19.1% of the control and 22.9% of the vaccine group. The prevalence increased with increasing age in both groups. The prevalence of VT serotypes in control groups aged 2 months, 4 months, 12 months, and 18 months was 40.9%, 44.2%, 53.8%, and 54.3%, respectively, and in the vaccine group, 25.9%, 40.4%, 38.0%, and 22.6%, respectively. The most common VT serotypes in both groups were 6A/6B, 19F, 23F, and 14. The prevalence of VT serotypes decreased significantly compared to non-vaccine type serotypes after three doses of the PCV13 vaccine (p < 0.001). Another notable change was the decline in prevalence of serotype 6A/6B after PCV13 administration using the 2+1 schedule. Conclusions This study shows lower prevalence of VT and 6A/6B serotypes in the nasopharynx among children who were PCV13 vaccinated compared with those who were unvaccinated. The result from this study will be the beginning of future vaccine evaluation in larger population and longer period of study. © 2021 Prayitno et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
|
Pneumococcus vaccine; 13-valent pneumococcal vaccine; Pneumococcus vaccine; Article; bacterial colonization; bacterium carrier; cohort analysis; controlled study; demography; female; follow up; human; human experiment; Indonesia; infant; male; multiplex polymerase chain reaction; nasopharynx; normal human; population research; prevalence; primary medical care; serotype; sex ratio; social status; Streptococcus pneumoniae; toddler; trend study; vaccination; immunology; isolation and purification; microbiology; nose mucosa; pathogenicity; pneumococcal infection; preschool child; procedures; Streptococcus pneumoniae; Child, Preschool; Female; Humans; Indonesia; Infant; Male; Nasal Mucosa; Pneumococcal Infections; Pneumococcal Vaccines; Streptococcus pneumoniae; Vaccination |
Public Library of Science |
19326203 |
|
33497405 |
Article |
Q1 |
990 |
4434 |
|
|
888 |
Subekti I., Kartiko G.J., Suhardi Z.F., Muhadi, Wisnu W. |
24336854300;57221818935;57221814580;57189615533;57200425452; |
Serum TSH level as predictor of Graves' disease recurrence following antithyroid drug withdrawal: A systematic review |
2021 |
PLoS ONE |
16 |
1 January |
e0245978 |
|
|
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100298149&doi=10.1371%2fjournal.pone.0245978&partnerID=40&md5=68971152ed2933aff2d374d62012a231 |
Faculty of Medicine, Division of Endocrinology and Metabolism, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital, Universitas Indonesia, Jakarta, Indonesia; Faculty of Medicine, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital, Universitas Indonesia, Jakarta, Indonesia; Faculty of Medicine, Division of Cardiology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital, Universitas Indonesia, Jakarta, Indonesia |
Subekti, I., Faculty of Medicine, Division of Endocrinology and Metabolism, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital, Universitas Indonesia, Jakarta, Indonesia; Kartiko, G.J., Faculty of Medicine, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital, Universitas Indonesia, Jakarta, Indonesia; Suhardi, Z.F., Faculty of Medicine, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital, Universitas Indonesia, Jakarta, Indonesia; Muhadi, Faculty of Medicine, Division of Cardiology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital, Universitas Indonesia, Jakarta, Indonesia; Wisnu, W., Faculty of Medicine, Division of Endocrinology and Metabolism, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital, Universitas Indonesia, Jakarta, Indonesia |
Graves' disease (GD) has a high recurrence rate despite various and adequate treatment. Numerous studies have been performed to identify the predictor of disease recurrence. This report aims to investigate the role of thyroid stimulating hormone (TSH) level as a thyrotropin in predicting the recurrence of Graves' disease within 1 to 2 years following antithyroid drug (ATD) withdrawal. Literature searching was conducted on PubMed, Scopus, Cochrane, Proquest, EBSCO in August 2019 and Google Scholar in October 2020. The study criteria include the study that evaluates TSH level 4 weeks following ATD withdrawal, with subjects ≥18 years old who are retrospectively or prospectively followed up after 1 to 2 years following ATD withdrawal. Four eligible studies were selected based on inclusion/exclusion criteria, all of which measured TSH level at 4 weeks following ATD withdrawal. All studies had 1 to 2 years follow up. One study was an RCT, two studies were done in prospective cohort and another in retrospective cohort. All studies had comparable validity and applicability. Three out of four studies suggested that low TSH level measured 4 weeks following treatment withdrawal was associated with higher risk of disease recurrence. In conclusion, low TSH level obtained 4 weeks after ATD withdrawal was associated with higher rate of recurrence rate in GD. Copyright: © 2021 Subekti et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
|
antithyroid agent; thyrotropin; antithyroid agent; thyrotropin; Article; clinical evaluation; clinical outcome; disease association; drug withdrawal; follow up; Graves disease; human; prospective study; recurrence risk; recurrent disease; risk factor; systematic review; thyrotropin blood level; blood; Graves disease; recurrent disease; treatment withdrawal; Antithyroid Agents; Graves Disease; Humans; Recurrence; Thyrotropin; Withholding Treatment |
Public Library of Science |
19326203 |
|
33513181 |
Article |
Q1 |
990 |
4434 |
|
|
No records
|
912 |
Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., Whitehead W.E., Dumitrascu D.L., Fang X., Fukudo S., Kellow J., Okeke E., Quigley E.M.M., Schmulson M., Whorwell P., Archampong T., Adibi P., Andresen V., Benninga M.A., Bonaz B., Bor S., Fernandez L.B., Choi S.C., Corazziari E.S., Francisconi C., Hani A., Lazebnik L., Lee Y.Y., Mulak A., Rahman M.M., Santos J., Setshedi M., Syam A.F., Vanner S., Wong R.K., Lopez-Colombo A., Costa V., Dickman R., Kanazawa M., Keshteli A.H., Khatun R., Maleki I., Poitras P., Pratap N., Stefanyuk O., Thomson S., Zeevenhooven J., Palsson O.S. |
55222586700;57224646613;57189767321;7005966711;57202571330;7102745366;16154954100;7005124531;57220861049;57219719431;57204305024;6701372042;7103105068;55993764500;35243963700;56401993900;56229001100;13805283000;7003532912;7004197628;7004013649;6701734343;7408119608;7006168774;6603069136;57204159889;7005446863;56191149300;6603579531;57216556340;7402389020;36469259800;8443384400;7005049888;55499852700;6504805230;56435522900;35965540900;7202046963;15765371700;57212081425;18935849300;35944673000;35249230500;56657486600;7202276913;57191854958;6603768529; |
Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study |
2021 |
Gastroenterology |
160 |
1 |
|
99 |
114.e3 |
|
233 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097793980&doi=10.1053%2fj.gastro.2020.04.014&partnerID=40&md5=db0ef85211fc480b0dc645b05ce86665 |
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Population Health Research Institute, McMaster University, Hamilton, ON, Canada; Center for Functional GI & Motility Disorders, University of North Carolina, Center for Education and Practice of Biopsychosocial Care, and Drossman Gastroenterology, Chapel Hill, NC, United States; Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGI), Lucknow, India; Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Translational Research Center for Gastrointestinal Disorders (TARGID), University of Leuven, Leuven, Belgium; Center for Functional GI & Motility Disorders, University of North Carolina-Chapel Hill, Chapel Hill, NC, United States; Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan; Discipline of Medicine, Northern Clinical School, University of Sydney, Sydney, Australia; Department of Medicine, University of Jos, Jos University Teaching Hospital, Jos, Nigeria; Lynda K. and David M. Underwood Center for Digestive Disorder, Gastroenterology and Hepatology, Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, United States; Laboratory of Liver, Pancreas and Motility (HIPAM), Unit of Research in Experimental Medicine, Faculty of Medicine, Universidad Nacional Autónoma de Mexico (UNAM). Hospital General de México, Mexico City, Mexico; Neurogastroenterology Unit, Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom; Department of Medicine, University of Ghana School of Medicine and Dentistry, Accra, Ghana; Integrative Functional Gastroenterology Research Center, Department of Internal Medicine, School of Medicine, Isfahan University of Medical SciencesIsfahan, Iran; Department of Medicine, Israelitic Hospital, Hamburg, Germany; Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Pediatric Gastroenterology, Amsterdam, The Netherlands, Netherlands; Service d'Hépato-Gastroentérologie, CHU Grenoble Alpes, Grenoble, France; Ege University School of Medicine, Division of Gastroenterology, Bornova Izmir, Turkey; “Centro Medico Dr. Bustos Fernandez”, Buenos Aires, Argentina; Department of Gastroenterology, School of Medicine, Wonkwang University, Iksan, South Korea; Department of Gastroenterology, Istituto Clinico Humanitas, Rozzano, Italy; Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Gastroenterology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; Gastroenterology Unit, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia; Department of Outpatient Medicine, Faculty of Internal Medicine, Moscow State University of Medicine and Dentistry, Moscow, Russian Federation; School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Kelantan, Malaysia; Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, Poland; Dhaka Medical College & Hospital, Dhaka, Bangladesh; Department of Gastroenterology, University Hospital Vall d'Hebron, Autonomous University of Barcelona & Neuro-Inmuno-Gastroenterology Lab, Vall d'Hebron Research Institute, Barcelona, Spain; Department of Medicine, Division of Gastroenterology, University of Cape Town, Cape Town, South Africa; Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Gastrointestinal Diseases Research Unit, Kingston Health Science Centre, Queen's University, Kingston, ON, Canada; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore; UMAE Hospital de Especialidades C.M.N. Manuel Avila Camacho, Puebla Pue, Mexico; Division of Gastroenterology, Rabin Medical Center, Sackler School of Medicine, Tel-Aviv, Israel; CEGIIR-Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, Canada; Gut and Liver Research Center, Department of Internal Medicine, Mazandaran University of Medical Sciences, Sari, Iran; CHUM, Université de Montréal, Montréal, QC, Canada; KIMS Hospitals, Secunderabad, India; Department of Biochemical Markers of Chronic Non-Communicable Diseases Research National Medical Research Centre for Preventive Medicine, Moscow, Russian Federation |
Sperber, A.D., Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Bangdiwala, S.I., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Population Health Research Institute, McMaster University, Hamilton, ON, Canada; Drossman, D.A., Center for Functional GI & Motility Disorders, University of North Carolina, Center for Education and Practice of Biopsychosocial Care, and Drossman Gastroenterology, Chapel Hill, NC, United States; Ghoshal, U.C., Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGI), Lucknow, India; Simren, M., Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Tack, J., Translational Research Center for Gastrointestinal Disorders (TARGID), University of Leuven, Leuven, Belgium; Whitehead, W.E., Center for Functional GI & Motility Disorders, University of North Carolina-Chapel Hill, Chapel Hill, NC, United States; Dumitrascu, D.L., Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Fang, X., Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Fukudo, S., Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan; Kellow, J., Discipline of Medicine, Northern Clinical School, University of Sydney, Sydney, Australia; Okeke, E., Department of Medicine, University of Jos, Jos University Teaching Hospital, Jos, Nigeria; Quigley, E.M.M., Lynda K. and David M. Underwood Center for Digestive Disorder, Gastroenterology and Hepatology, Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, United States; Schmulson, M., Laboratory of Liver, Pancreas and Motility (HIPAM), Unit of Research in Experimental Medicine, Faculty of Medicine, Universidad Nacional Autónoma de Mexico (UNAM). Hospital General de México, Mexico City, Mexico; Whorwell, P., Neurogastroenterology Unit, Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom; Archampong, T., Department of Medicine, University of Ghana School of Medicine and Dentistry, Accra, Ghana; Adibi, P., Integrative Functional Gastroenterology Research Center, Department of Internal Medicine, School of Medicine, Isfahan University of Medical SciencesIsfahan, Iran; Andresen, V., Department of Medicine, Israelitic Hospital, Hamburg, Germany; Benninga, M.A., Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Pediatric Gastroenterology, Amsterdam, The Netherlands, Netherlands; Bonaz, B., Service d'Hépato-Gastroentérologie, CHU Grenoble Alpes, Grenoble, France; Bor, S., Ege University School of Medicine, Division of Gastroenterology, Bornova Izmir, Turkey; Fernandez, L.B., “Centro Medico Dr. Bustos Fernandez”, Buenos Aires, Argentina; Choi, S.C., Department of Gastroenterology, School of Medicine, Wonkwang University, Iksan, South Korea; Corazziari, E.S., Department of Gastroenterology, Istituto Clinico Humanitas, Rozzano, Italy; Francisconi, C., Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Gastroenterology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; Hani, A., Gastroenterology Unit, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia; Lazebnik, L., Department of Outpatient Medicine, Faculty of Internal Medicine, Moscow State University of Medicine and Dentistry, Moscow, Russian Federation; Lee, Y.Y., School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Kelantan, Malaysia; Mulak, A., Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, Poland; Rahman, M.M., Dhaka Medical College & Hospital, Dhaka, Bangladesh; Santos, J., Department of Gastroenterology, University Hospital Vall d'Hebron, Autonomous University of Barcelona & Neuro-Inmuno-Gastroenterology Lab, Vall d'Hebron Research Institute, Barcelona, Spain; Setshedi, M., Department of Medicine, Division of Gastroenterology, University of Cape Town, Cape Town, South Africa; Syam, A.F., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Vanner, S., Gastrointestinal Diseases Research Unit, Kingston Health Science Centre, Queen's University, Kingston, ON, Canada; Wong, R.K., Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore; Lopez-Colombo, A., UMAE Hospital de Especialidades C.M.N. Manuel Avila Camacho, Puebla Pue, Mexico; Costa, V., Gastroenterology Unit, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia; Dickman, R., Division of Gastroenterology, Rabin Medical Center, Sackler School of Medicine, Tel-Aviv, Israel; Kanazawa, M., Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan; Keshteli, A.H., CEGIIR-Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, Canada; Khatun, R., Population Health Research Institute, McMaster University, Hamilton, ON, Canada; Maleki, I., Gut and Liver Research Center, Department of Internal Medicine, Mazandaran University of Medical Sciences, Sari, Iran; Poitras, P., CHUM, Université de Montréal, Montréal, QC, Canada; Pratap, N., KIMS Hospitals, Secunderabad, India; Stefanyuk, O., Department of Biochemical Markers of Chronic Non-Communicable Diseases Research National Medical Research Centre for Preventive Medicine, Moscow, Russian Federation; Thomson, S., Department of Medicine, Division of Gastroenterology, University of Cape Town, Cape Town, South Africa; Zeevenhooven, J., Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Pediatric Gastroenterology, Amsterdam, The Netherlands, Netherlands; Palsson, O.S., Center for Functional GI & Motility Disorders, University of North Carolina-Chapel Hill, Chapel Hill, NC, United States |
Background & Aims: Although functional gastrointestinal disorders (FGIDs), now called disorders of gut-brain interaction, have major economic effects on health care systems and adversely affect quality of life, little is known about their global prevalence and distribution. We investigated the prevalence of and factors associated with 22 FGIDs, in 33 countries on 6 continents. Methods: Data were collected via the Internet in 24 countries, personal interviews in 7 countries, and both in 2 countries, using the Rome IV diagnostic questionnaire, Rome III irritable bowel syndrome questions, and 80 items to identify variables associated with FGIDs. Data collection methods differed for Internet and household groups, so data analyses were conducted and reported separately. Results: Among the 73,076 adult respondents (49.5% women), diagnostic criteria were met for at least 1 FGID by 40.3% persons who completed the Internet surveys (95% confidence interval [CI], 39.9–40.7) and 20.7% of persons who completed the household surveys (95% CI, 20.2–21.3). FGIDs were more prevalent among women than men, based on responses to the Internet survey (odds ratio, 1.7; 95% CI, 1.6–1.7) and household survey (odds ratio, 1.3; 95% CI, 1.3–1.4). FGIDs were associated with lower quality of life and more frequent doctor visits. Proportions of subjects with irritable bowel syndrome were lower when the Rome IV criteria were used, compared with the Rome III criteria, in the Internet survey (4.1% vs 10.1%) and household survey (1.5% vs 3.5%). Conclusions: In a large-scale multinational study, we found that more than 40% of persons worldwide have FGIDs, which affect quality of life and health care use. Although the absolute prevalence was higher among Internet respondents, similar trends and relative distributions were found in people who completed Internet vs personal interviews. © 2021 The Authors |
DGBI; epidemiology; IBS |
abdominal pain; adult; anorectal disease; Article; biliary tract pain; comparative study; confidence interval; data analysis; descriptive research; digestive system function disorder; disease burden; duodenum disease; esophagus disease; female; gastrointestinal disease; human; information processing; Internet; irritable colon; Italy; major clinical study; male; prevalence; priority journal; quality of life; questionnaire; Research Diagnostic Criteria; adolescent; age distribution; aged; gastrointestinal disease; global health; middle aged; sex ratio; young adult; Adolescent; Adult; Age Distribution; Aged; Female; Gastrointestinal Diseases; Global Health; Humans; Male; Middle Aged; Prevalence; Sex Distribution; Surveys and Questionnaires; Young Adult |
W.B. Saunders |
00165085 |
|
32294476 |
Article |
Q1 |
7828 |
131 |
|
|